Application of grincamycin B in preparing anti-glioma drugs

A technique for gliclamycin and glioma, which is applied in the medical field to achieve the effects of improving the effect of tumor treatment, improving the quality of life and low production cost

Inactive Publication Date: 2014-02-05
THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, whether grekamicin series compounds have the effect of anti-tumor stem cells and

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of grincamycin B in preparing anti-glioma drugs
  • Application of grincamycin B in preparing anti-glioma drugs
  • Application of grincamycin B in preparing anti-glioma drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Example 1 Inhibition Rate of Glikamicin Series Compounds of Different Concentrations on Malignant Glioma Cell Lines

[0038] CCK8 (purchased from Biyuntian, product number: C0038) was used to detect the inhibition rate of different concentrations of grekamicin series compounds on malignant glioma cell lines, and the steps were as follows:

[0039] 1. Take the U251 cell line with good growth state from the 3rd to the 10th generation, and adjust it to 5×10 4 Cells at a concentration of / mL, 100 μL per well, cultured in a 96-well plate, adhered to the wall overnight;

[0040] 2. The experimental group was added with gricomycin series compounds (the final concentrations were 8, 4, 2, 1, 0.5 and 0.25 μM respectively) (the concentration of the mother solution of grikamicin series compounds was 10 mM, dissolved in dimethyl sulfoxide (DMSO) (Amresco, product number: D8370), stored at -20°C), the control group was culture medium with a final concentration of 0.05% (v / v) DMSO, a...

Embodiment 2

[0048] Example 2 Grecomycin B induces apoptosis of malignant glioma U251 cell line

[0049] The FACS Calibur flow cytometer (BD Company, USA) was used to detect the apoptosis induced by gricomycin B on the malignant glioma U251 cell line, and the method was as follows:

[0050] 1. Take the U251 cell line with good growth state from the 3rd to the 10th generation, and adjust it to 5×10 4 Cells at a concentration of / mL were cultured in a 6-well plate, 2mL / well, and adhered to the wall overnight;

[0051] 2. The culture medium was replaced, the experimental group was the culture medium of the gratamicin B compound with the final concentration of 1.0 μM and 2.0 μM respectively, and the control group was the culture medium of the DMSO with the final concentration of 0.05% (v / v);

[0052] 3. Placed at 37°C, CO 2 The gas volume fraction was 5% cultured in an incubator. After 48 hours, the cells of each group were digested and collected for flow cytometry to detect the apoptosis in...

Embodiment 3

[0054] Example 3 Influence of Grecomycin B on Cell Cycle of U251 Cell Line of Malignant Glioma

[0055] FACS Calibur flow cytometry was used to detect the effect of gricomycin B on the cell cycle of malignant glioma U251 cell line, and the method was as follows:

[0056] 1. Take the U251 cell line with good growth state from the 3rd to the 10th generation, and adjust it to 5×10 4 Cells at a concentration of / mL were cultured in a 6-well plate, 2mL / well, and adhered to the wall overnight;

[0057] 2. Replace the culture medium and add the gratamicin B compound with final concentrations of 1.0 μM and 2.0 μM respectively, and the control group is the culture medium with DMSO at the final concentration of 0.05% (v / v);

[0058] 3. Placed at 37°C, CO 2 The gas volume fraction was 5% cultured in an incubator. After 48 hours, the cells in each group were digested and collected for flow cytometry to detect the effect of gricomycin B on the cell cycle of the malignant glioma U251 cell...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the medical field and discloses an application of a grincamycin B compound in preparing anti-glioma drugs. According to the invention, the grincamycin B has selective action on glioblastoma cells, and also has very good biological activity; the grincamycin B acts in inducing the apoptosis of tumor cells and tumor stem cells and blocking cells at the stages G0-G1; the grincamycin B effectively inhibits glioma cloning; the grincamycin B effectively inhibits the formation of glioma stem cells; the grincamycin B effectively inhibits the expression of the dry gene of the glioma stem cells, and further is capable of effectively inhibiting the self-updating effect of the glioma stem cells; therefore, the grincamycin B is a potential anti-cancer drug and provides a new scheme and a new drug for oncotherapy of targeted cancer stem cells (CSC); and furthermore, the grincamycin B plays an important role in improving the oncotherapy effect and improving the life quality of a patient.

Description

technical field [0001] The invention belongs to the medical field, and relates to a new application of a gramamicin B compound, in particular to an application of the gramamicin B compound in the preparation of anti-glioma drugs. Background technique [0002] Malignant tumors are diseases with high morbidity and high mortality that seriously endanger human health. Glioma [0003] (glioma) is a tumor caused by glial cells (astrocytes, oligodendrocytes, ependyma, etc.) differentiated from the neuroectoderm, and its incidence rate ranks first among intracranial tumors. According to the 2007 WHO classification of tumors of the central nervous system, malignant gliomas are defined as glioblastomas higher than or equal to WHO grade III, specifically including anaplastic astrocytoma (grade III), anaplastic oligodendroglioma (grade III) grade), anaplastic oligoastrocytoma (grade III), glioblastoma (grade IV) and giant cell glioblastoma (grade IV), the first three of which can be c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7032A61P35/00
Inventor 姚月良平轶芳卞修武
Owner THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap